thrombocytopenic purpura


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to thrombocytopenic purpura: thrombotic thrombocytopenic purpura
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.thrombocytopenic purpura - purpura associated with a reduction in circulating blood platelets which can result from a variety of factors
autoimmune disease, autoimmune disorder - any of a large group of diseases characterized by abnormal functioning of the immune system that causes your immune system to produce antibodies against your own tissues
peliosis, purpura - any of several blood diseases causing subcutaneous bleeding
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
References in periodicals archive ?
In the U.S., idiopathic thrombocytopenic purpura (ITP) impacts the lives of 4-8per 100,000 children under the age of 15 each year in the U.S.
Over the next 12-15 months, we anticipate key readouts from our clinical candidates, including top-line data in 2020 from our Phase 2 studies of nipocalimab in generalized myasthenia gravis and M254 in Immune Thrombocytopenic Purpura."
Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology.
It was launched for the treatment of idiopathic thrombocytopenic purpura (ITP) and has contributed to many ITP patients since April 2011.
Immune thrombocytopenic purpura (ITP) is a syndrome that reduces platelet levels, and it is caused by the development of autoantibodies against thrombocytes.
M2 EQUITYBITES-February 7, 2019-Sanofi wins US FDA approval for Cablivi for treating acquired thrombotic thrombocytopenic purpura
Global Banking News-February 7, 2019-Sanofi wins US FDA approval for Cablivi for treating acquired thrombotic thrombocytopenic purpura
M2 PHARMA-February 7, 2019-Sanofi wins US FDA approval for Cablivi for treating acquired thrombotic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura (TTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and organ dysfunction.
The record of 103 patients was reviewed retrospectively during the study period, diagnosed as acute Idiopathic Thrombocytopenic Purpura. The median age, at the time of presentation, was 5+-3.4 years while mean age was 4.5+-2.9 years.
Objective: To assess clinical presentation and outcome of patients with thrombotic thrombocytopenic purpura (TTP) in our setup.